The historical rank and industry rank for Cell Source's Days Inventory or its related term are showing as below:
CLCS's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 184.145 * Ranked among companies with meaningful Days Inventory only.
Cell Source's Days Inventory
stayed the same
from Dec. 2023 (0.00) to Dec. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cell Source (OTCPK:CLCS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cell Source's Inventory Turnover for the
three
months ended in Dec. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cell Source's Inventory to Revenue for the
three
months ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Cell Source Days Inventory Related Terms
Cell Source Days Inventory Historical Data
* Premium members only.
The historical data trend for Cell Source's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLCS vs EDSA, CTXR, ASBP: Days Inventory Comparison
For the Biotechnology subindustry, Cell Source's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Source Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cell Source's Days Inventory distribution charts can be found below:
* The bar in red indicates where Cell Source's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Source (CLCS) has a Days Inventory of 0.00 as of Dec. 2024. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cell Source and its competitors.
Is Cell Source's Days Inventory too high?
Cell Source's current Days Inventory is 0.00. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Days Inventory compare to EDSA and CTXR?
Cell Source's Days Inventory of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Inventory is 184.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Cell Source (CLCS), the current Days Inventory is 0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score
Get the complete analysis for CLCS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLCS has been successfully added to your 
